AllianceBernstein
RIGL icon

AllianceBernstein’s Rigel Pharmaceuticals RIGL Stock Holding History

AllianceBernstein’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$1.15M – 3133
2018
Q4 		$1.15M Buy
+50,000
New +$1.41M ﹤0.01% 2130

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's RIGL Position: Q2 2026 in Review

AllianceBernstein increased its Rigel Pharmaceuticals (RIGL) stake by 86% in Q2 2026, buying an estimated $456K and bringing the position to 32,033 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

AllianceBernstein first reported a position in RIGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.31M in Q3 2018. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • AllianceBernstein held 32,033 shares of Rigel Pharmaceuticals worth $866K as of Q2 2026.
  • AllianceBernstein bought 14,800 Rigel Pharmaceuticals shares in Q2 2026, an estimated $456K.
  • Rigel Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2450 holding.
  • AllianceBernstein first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • AllianceBernstein's Rigel Pharmaceuticals position peaked at $4.31M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.